G&H, a fast-growing global leader in the life science manufacturing sector, will showcase its latest bioscience innovations and capabilities at the 2024 Association for Diagnostic and Laboratory Medicine (ADLM) Clinical Laboratory Expo, taking place at McCormick Place in Chicago, Illinois from July 30 to August 1, 2024. This year’s conference theme revolves around Bold Advancements in Global Clinical Laboratory Medicine, a powerful statement that will be highlighted throughout G&H’s conference.
With an award-winning medical device manufacturing process in place, the company plans to further diversify its strong position as a trusted medical device and equipment supplier. Next to the specific medical technology exhibits on offer at booth number 1249, G&H will focus on improving the broad design scope and feasibility of life science technology solutions. This strategic direction reflects the need to solve two of the most pressing challenges in the healthcare sector: long development times and supplier security vulnerabilities.
According to the 2024 BDO Annual Survey of Life Sciences CFOs, 41% of life sciences CFOs plan to make strategic changes to procurement and vendor contracts in 2024 due to supply chain risks. Such intentions are a direct result of the cumulative disruptions that have occurred in the international medical technology design and production cycle over the past five years, especially during the COVID-19 pandemic. G&H aims to address these economically demanding challenges with a focus on seamless vertical integration through increased manufacturing capabilities. The multidisciplinarity and heritage of knowledge that characterize G&H’s life sciences R&D team minimizes the time gaps between the various manufacturing touchpoints found in the sector’s traditional production cycle.
Additionally, G&H is expanding into the US market through its upcoming Life Sciences Innovation Hub in Rochester, New York, addressing specific customer expectations in the North American region. As such, the already established “Made in the USA” quality of G&H’s innovations will extend to Life Sciences, especially in terms of technology, timeline efficiency, regulations and cost management. With the broad range of application umbrellas hosted by the G&H Group worldwide, its holistic approach to medical technology development will lead to an accelerated time to value in this market space, delivering immediate benefits to its customers.
“The conversations our team will have at this year’s ADLM will be a turning point in how we collaborate with our clients and stakeholders,” said Brian Boswell, Executive Vice President, Life Sciences, G&H. “The key word for our presence in Chicago is scope. More specifically, we aim to explore client-side possibilities more holistically than ever before. Given the impressive range of medical technology solutions G&H offers internationally and our cutting-edge design capabilities, this approach feels like a natural next step to welcome new projects that can go from prototype to market in record time. The life sciences sector is currently the largest sector in the global healthcare industry and is poised for rapid expansion in terms of innovation and revenue. This makes it essential that we foster unique touchpoints between high-tech enablers and providers to co-create the world’s next breakthroughs. After all, we are talking about actions that directly impact the quality of human life. We think future clients will be impressed with the breadth of possibilities in medical technology that we can deliver through G&H’s global manufacturing capabilities, from creating rough prototypes to providing the last simple consumables needed for the design.”
Conference attendees can schedule a meeting with the G&H team to discuss end-to-end development opportunities for medical applications. Book here and come to booth #1249 to start the conversation about the future of biotech solutions.
